New AIRR-C Diagnostics Working Group initiated
Antibody Engineering & Therapeutics, December 2019
Thank you for joining us at The Antibody Society’s annual Antibody Engineering & Therapeutics meeting held December 9-13, 2019 in San Diego. The meeting was a great opportunity for Society members to connect with industry and academic scientists and executives from around the world, and learn about advances in antibody discovery and development.
As always, The Antibody Society’s members designed the scientific program and acted as session Chairs. The meeting featured sessions on Antibody Libraries, Selection, Screening and Engineering; Bioinformatics and Computational Tools for Antibody Optimization and Engineering; Clinical Data and Lessons from Cancer Immunotherapy; Systems Immunology for Target Discovery; and Targeting Subcellular Trafficking Pathways to Generate Antibody Therapeutics.
AE&T Student/Postdoc Poster Competition
The Society sponsored a poster competition for students and postdocs, with winners receiving complimentary registration, support for travel expenses, and an opportunity to present at the conference. Congratulations to the winners:
Timothy Czajka, University of New York at Albany. Poster title: RIP-Off: An Intrabody-based Strategy to Neutralize Ricin and other Ribosome-Inactivating Protein (RIP) Toxins.
Kamal Joshi, PhD., Genentech. Poster title: Toward Deeper Understanding of Bispecific Antibodies
“Thank you again to the Antibody Society for this recognition and opportunity to speak here. This is my third time attending the Antibody Engineering and Therapeutics conference and each time I’ve learned more than I could possibly remember and return to the lab with a huge surge of excitement and several new ideas that I’d like to apply to my own project. I’m honored to be able to present my own research this year alongside so many fascinating talks and to be able to engage with many different experts in the field. I would also like to thank my advisor, Nicholas Mantis, and Anne Messer for their help with my research and encouragement to attend and apply for this award.” Timothy Czajka
“It is an honor to receive this award. I would like to thank the judges for conferring this recognition on my work. I would also like to thank the Antibody Society, of course for funding my trip here but more importantly for organizing these fantastic meetings and providing a solid platform for the exchange of the latest information on antibody research and development benefiting all including early stage career scientists like me. It’s a real treat coming back to this meeting every time. Not only do I learn what is ongoing in the field, this meeting also provides me the opportunity to network with fellow scientists and facilitate connections. So again, thank you to the Antibody Society for this award. Thank you all.” Kamal Joshi, Ph.D.
Moments at Antibody Engineering & Therapeutics
We look forward to seeing you at AE&T in December 2020!
All Society members receive discounts on registration to Antibody Engineering & Therapeutics (US), as well as registration at many antibody-related meetings.
Student/Post-doc Poster Competition Winners Announced!
Congratulations to our winners!
To recognize the research activities of promising student and postdoctoral attendees of Antibody Engineering & Therapeutics, The Antibody Society sponsors a competition for our student/postdoc members who submit posters for display at the meeting. Our judges select the best work based on originality, relevance and perceived impact on the field of antibody R&D.
This year, our judges selected one student and one postdoc winners who receive: 1) a complimentary registration to attend the conference and pre-conference sessions; 2) an opportunity to give a short oral presentation of their work in one of the conference sessions; and 3) support for travel expenses.
The winners of the contest are:
Timothy Czajka, University of New York at Albany (graduate student winner)
Poster title: RIP-Off: An Intrabody-based Strategy to Neutralize Ricin and other Ribosome-Inactivating Protein (RIP) Toxins
Kamal Joshi, Genentech (Postdoctoral research fellow winner)
Poster title: Toward Deeper Understanding of Bispecific Antibodies
Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, managed by KNect365, will be held December 10-13, 2019 in San Diego, CA.
Society members receive a 15% discount on the registration fee. Contact us at membership@antibodysociety.org for the code.
Like this post but not a member? Please join!
World ADC Award Winners Announced
The Antibody Society congratulates the winners of World ADC Awards!
World ADC Awards showcases the innovation, leadership and devotion shown by the best companies, teams and individuals in the industry. Across 9 categories, the Awards recognized the extraordinary endeavours, teamwork and commercial acumen that has propelled the antibody-drug conjugate field to the forefront of cancer research today. The 6th Annual World ADC Awards Ceremony took place on the evening of Thursday October 10, 2019 at the Manchester Grand Hyatt, San Diego. The finalists and winners were shortlisted from over 1,147 votes cast, and scientific proposals from each submission were evaluated by the Judging panel.
The 2019 winners are:
Best ADC Platform Technology
Zymeworks (ZymeLink) – Winner
LegoChem Bio (Scaffold Based Approach) – Runner Up
Best New Drug Developer
ADC Therapeutics – Winner
Zymeworks – Runner Up
Most Promising Clinical Candidate
Trastuzumab Deruxtecan (DS-8201a) – Winner
Enfortumab Vedotin (Seattle Genetics/Astella) – Runner Up
Best Contract Manufacturing Provider
BSP Pharmaceuticals – Winner
Millipore Sigma – Runner Up
Best Contract Research Provider
PPD – Winner
Abzena – Runner Up
Best Pre-Clinical Publication
Winner: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS. Nat Commun. 2018 May 4;9(1):1484.
Runner Up: Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S, Dal Corso A, Widmayer F, Neri D. J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.
Best Clinical Publication
Winner: Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.
Individual Input to the Field 2018
Prof. Dario Neri (ETH Zurich)
Long-Standing Contribution to the Field
Dr. Alain Beck (Pierre Fabre)
For more information about the World ADC Awards, visit http://worldadc-awards.com/
For more information about the World ADC San Diego conference, visit https://worldadc-usa.com/